Clinical Trials Sponsored by Sanko University

Total 221845 results

Daiichi Sankyo, Inc.

Completed

DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix

Cervical Cancer

United States
Daiichi Sankyo, Inc.

Completed

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Daiichi Sankyo, Inc.

Terminated

CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin

Metastatic Colorectal Cancer

United Kingdom
Daiichi Sankyo, Inc.

Completed

Olmesartan Comparison to Losartan in Hypertensive Subjects

Hypertension

United States
Daiichi Sankyo, Inc.

Completed

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

Hypertension

United States
Daiichi Sankyo, Inc.

Completed

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension (Benibest)

Essential Hypertension
Daiichi Sankyo, Inc.

Completed

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Daiichi Sankyo, Inc.

Terminated

The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis

Symptomatic Hip Osteoarthritis

France
Daiichi Sankyo, Inc.

Completed

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Diabetes Mellitus, Type 2

United States
Daiichi Sankyo, Inc.

Completed

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Hypertension | Metabolic Syndrome | Insulin Resistance

United States
Daiichi Sankyo, Inc.

Completed

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Healthy
Federal University of Espirito Santo

Recruiting

Effects of SARAH Protocol in Women With Rheumatoid Arthritis

Rheumatoid Arthritis

Brazil
Federal University of Espirito Santo

Enrolling by invitation

Identify the Prosthesis Users' Necessities Concerning Their Devices.

Upper Limb Amputation at the Hand

Brazil
Federal University of Espirito Santo

Completed

Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises

Fibromyalgia

Brazil
University Hospital Heidelberg
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)

Acute Myeloid Leukemia
Daiichi Sankyo, Inc.
Daiichi Sankyo (China) Holdings Co., Ltd.

Active, not recruiting

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Non-valvular Atrial Fibrillation

China
Daiichi Sankyo Co., Ltd.
AstraZeneca

Completed

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Neoplasm, Gastrointestinal

Korea, Republic of, Japan
Daiichi Sankyo, Inc.
Daiichi Sankyo Korea Co., Ltd.

Completed

An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Dyslipidemia Associated With Type II Diabetes Mellitus

Korea, Republic of
Daiichi Sankyo Co., Ltd.
AstraZeneca; Daiichi Sankyo, Inc.

Completed

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Colorectal Neoplasm

United States, Spain, Japan, Italy, United Kingdom
UNICANCER
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Active, not recruiting

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis (DAISY)

Breast Tumors

France
Georgetown University
Daiichi Sankyo, Inc.

Terminated

Phase I Study of CS-7017 and Bexarotene

Lymphoma | Multiple Myeloma | Solid Tumors

United States
AstraZeneca
Daiichi Sankyo

Not yet recruiting

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada (HER-TEMPO)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Canada
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Japan, Brazil, Taiwan, Korea, Republic of, Australia, Austria, Canada, Poland, United States, Belgium, United Kingdom, Turkey, Hungary, Germany, India
Daiichi Sankyo
AstraZeneca

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Metastatic Cancer | Advanced Cancer

Spain, Korea, Republic of, Belgium, France, Italy, United States, Australia, Japan, Taiwan, United Kingdom
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

Spain, China, United States, Italy, United Kingdom, Korea, Republic of, Belgium, France, Germany, Poland, Japan, Vietnam, Canada, Brazil, India, Malaysia, Taiwan, Thailand, Australia, Austria, Turkey, Hong Kong, Bulgaria, Switzerland, H... and more
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, France, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Turkey, Brazil, Japan, Taiwan, Thailand, Canada, Singapore, Mexico, Argentina, Germany, India, Philippines, Poland, South Africa
MedSIR
Daiichi Sankyo

Not yet recruiting

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4)

Breast Cancer | Metastatic Breast Cancer
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Italy, Hong Kong, Belgium, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
AstraZeneca
Daiichi Sankyo

Recruiting

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)

Advanced or Metastatic NSCLC

United States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

United States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer; HER2-positive; Metastatic

United States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
Daiichi Sankyo, Inc.

Completed

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

HER2-positive Breast Cancer

China
Daiichi Sankyo, Inc.

Completed

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib (PLX3397)

Tenosynovial Giant Cell Tumor

United States, Spain, Taiwan, Australia, Hungary, Italy, Netherlands
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Daiichi Sankyo, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Netherton Syndrome

United States
Daiichi Sankyo, Inc.

Completed

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Systemic Lupus Erythematosus

United States
Daiichi Sankyo, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Netherton Syndrome

United States
Daiichi Sankyo, Inc.

Terminated

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States, Spain, Belgium, Japan, France, United Kingdom, Italy, Poland
Daiichi Sankyo, Inc.

Terminated

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Daiichi Sankyo, Inc.

Terminated

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Daiichi Sankyo, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Daiichi Sankyo, Inc.

Completed

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Germany, Mexico, Romania, Serbia, South Africa, Ukraine, Chile, Peru, Puerto Rico, Austria, Hungary, Slovakia, India, Czechia, Latvia, Argentina, United Kingdom
Daiichi Sankyo, Inc.

Completed

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Coronary Artery Disease

United States
Daiichi Sankyo, Inc.

Completed

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Moderate Hepatic Impairment

United States
Daiichi Sankyo, Inc.

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Daiichi Sankyo, Inc.

Completed

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States, Russian Federation, Germany, France, Italy
Daiichi Sankyo, Inc.

Completed

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB) (BEAD-MB)

Baseline Epidemiologic Assessment

United States

Clinical Trials Sponsored by Sanko University

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations